The study aims to study the efficacy of colostrum from MERS-CoV-positive camels appliedas a nasal spray to COVID-19 patients for treatment and prevention of SARS-CoV-2infection. This study will compare the usage of colostrum to placebo.
Not Provided
Biological: Colostrum Nasal Spray
24 hours use of nasal spray of colostrum from MERS-CoV positive camels- 6 doses total
Other: Water for injection
24 hours use of a nasal spray of water for injection- 6 doses total
Inclusion Criteria:
- Age over 18 years.
- Laboratory-proven infection with COVID-19 using PCR or another approved kit
- Hospitalized / community setting-at low-moderate clinical risk according to the
NEWS-2 scale with a score of 0-10.
- Onset of symptoms up to 7 days before inclusion
- Can sign informed consent
- Willingness and ability to participate in research
Exclusion Criteria:
- Pregnant women or lactating
- Lack of judgment (psychiatric disorder or dementia)
- Immunosuppressed - HIV with CD4 below 500, chemotherapy, steroids - more than 5 mg
per day, solid organ transplants, bone marrow transplants, active hematological or
oncological malignancies, biological therapy
- Neutropenia (less than 2000 neutrophils per cubic meter) or thrombocytopenia
(platelet count less than 50000 per cubic meter).
- Acute or chronic sinusitis.
- Nasal polyps or any pathology in the nasal cavity
- Cystic fibrosis
- Significant disturbance in liver functions (AST/ALT more than 5 times the ULN)
- Significant renal dysfunction (GFR lower than 30 ml per minute)
- Known allergy to colostrum or cow's milk
- Use of another study drug
Hadassah Hebrew University
Jerusalem, Israel
Not Provided